[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625185":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Glecaprevir\u002FPibrentasvir",null,"Data from participants prescribed Glecaprevir\u002Fpibrentasvir will be collected.",[13],{"name":14,"affiliation":5,"role":15},"ABBVIE INC.","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Dimitri Semizarov","CONTACT","+1 847-935-8741","dimitri.semizarov@abbvie.com",[23,37],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Vancouver Infectious Diseases Centre \u002FID# 275313","RECRUITING","Vancouver","British Columbia","V6Z 2C7","Canada","CA",{"type":32,"coordinates":33},"Point",[34,35],-123.11934,49.24966,{"lat":35,"lon":34},{"facility":38,"status":25,"city":39,"state":40,"zip":41,"country":29,"countryCode":30,"cosmosGeoPoint":42,"geoPoint":46,"contacts":10},"St. Clair Medical Clinic \u002FID# 275334","Toronto","Ontario","M4S 1Y2",{"type":32,"coordinates":43},[44,45],-79.39864,43.70643,{"lat":45,"lon":44},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100625185","study-of-glecaprevirpibrentasvir-to-assess-safety-through-real-world-data-100625185",false,"NCT07419347","Study of Glecaprevir\u002FPibrentasvir to Assess Safety Through Real-World Data","Retrospective Analysis of Glecaprevir\u002FPibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data","Inclusion Criteria:\n\n* Prescribed 8 weeks of Glecaprevir\u002FPibrentasvir (G\u002FP).\n* Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)\n* Is concomitantly on one or more prescription medications or illicit drugs.\n\nExclusion Criteria:\n\n* Treated with DAAs other than G\u002FP.\n* History of decompensated cirrhosis.\n* Had Hepatitis-B virus (HBV) infection.\n* Had hepatocellular carcinoma (HCC).","ALL","18 Years",{"count":59,"type":60},2000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir\u002FPibrentasvir (G\u002FP) in participants taking either prescribed or illicit drugs.",[64],"Hepatitis C Virus (HCV)",[64,66,67],"Glecaprevir","Pibrentasvir","2026-04-15",{"date":70,"type":71},"2026-04-16","ACTUAL",{"date":73,"type":71},"2026-02-27",{"date":75,"type":60},"2026-06",{"name":5,"class":6},2]